Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Potenza Therapeutics Inc.

http://potenzatherapeutics.com/index.php

Latest From Potenza Therapeutics Inc.

Japan 2010s In Review: Specialize, Focus, Innovate

Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.

Japan Reimbursement

Japan 2010s In Review: Specialize, Focus, Innovate

Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.

Japan Business Strategies

Five Topics That Shaped Japan Pharma In 2019

Looking back on the top stories about Japan in Scrip and the Pink Sheet over 2019, it is hard to avoid the continued dominance of corporate transactions - in particular those involving Takeda.

Japan Business Strategies

Astellas Strengthens Next-Gen I-O Hand With $665m Xyphos Buy

Astellas pays to play in next-generation immuno-oncology through deal for young, privately held US venture and its novel modulation platform.

M & A ImmunoOncology
See All

Company Information

UsernamePublicRestriction

Register